Minerva Neurosciences, Inc.
NERV•NASDAQ•Healthcare•Biotechnology

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORemy Luthringer
Founded2007
IPO DateJuly 1, 2014
Employees8
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.minervaneurosciences.com
Phone617 600 7373
Address
1500 District Avenue Burlington, Massachusetts 01803 United States

Corporate Identifiers

CIK0001598646
CUSIP603380205
ISINUS6033802058
EIN26-0784194
SIC2834

Leadership Team & Key Executives

Dr. Remy Luthringer Ph.D.
Executive Chairman and Chief Executive Officer
Geoffrey Robin Race F.C.M.A., M.B.A.
President
Frederick W. Ahlholm CPA
Senior Vice President, Chief Financial Officer and Secretary
Joseph Reilly
Senior Vice President and Chief Operating Officer
William B. Boni
Vice President of Investor Relations and Corporate Communications
Prof. Michael Davidson M.D.
Chief Medical Officer